Emmaus Life Sciences Announces Launch of Full-Service Telehealth Solution

Platform Providers Will Handle On-line Prescribing, Dispensing and Delivery of Endari®

TORRANCE, Calif., April 11, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the launch of an innovative full-service telehealth solution (https://www.endarirx.com/ask-physician) with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScriptHealth. The telehealth program capitalizes on the expansion of telemedicine in the U.S. to afford patients and providers on-line access to Endari®, the company's prescription-grade L-glutamine oral powder, for the treatment of sickle cell disease.

"The launch of our full-service telehealth solution reflects our stated commitment to make Endari accessible to sickle cell patients in need and we are excited to be launching the program," noted Yutaka Niihara, M.D., M.P.H., Emmaus' Chairman and Chief Executive Officer. "Our solution will allow patients to see a doctor without leaving home, thereby eliminating unnecessary travel time and expense and the risk of infection that can occur with hospital visits. Eligible patients will be able to receive a same-day physician authorization and prescription for Endari and to have the prescription delivered to their homes within just a few days. As the telehealth solution grows, we are optimistic that it will help us to reach new patients and add meaningful revenue for Emmaus."

According to a December 3, 2021 report from the U.S. Department of Health & Human Services (HHS), available at the HHS website at https://www.hhs.gov, the share of Medicare visits conducted through telehealth in 2020 increased 63-fold, from approximately 840,000 in 2019 to 52.7 million. The report noted that telehealth was particularly helpful in offsetting potential foregone behavioral health care and that states with the highest use of telehealth in 2020 included Massachusetts, Vermont, Rhode Island, New Hampshire, and Connecticut. Other industry sources suggest that the trend toward telehealth accelerated in 2021 and is likely to be sustained.

"We believe that affording patients and telehealth prescribers access to Endari in a quick and convenient way will improve their experience and potentially increase adherence rates," stated George Sekulich, Senior Vice President of Global Commercialization of Emmaus. "We look forward to working with our strategic partners on this important project."  

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets U.S. Food and Drug Administration approved Endari® (L-glutamine oral powder) indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as diverticulosis. For more information, please visit www.emmausmedical.com.

Indication - Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari at: www.EndariRx.com/PI.

There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.¹ The genetic mutation responsible for SCD causes an individual's red blood cells to distort into a "C" or a sickle shape, reducing their ability to transport oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together, which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads to physical symptoms of incapacitating pain, tissue and organ damage, and early death.²

¹Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020.
²Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the anticipated benefits of the company's new telehealth services. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including uncertainties regarding market acceptance of the company's telehealth solution and other risks and uncertainties disclosed in the company's 2021 Annual Report on Form 10-K filed with the SEC on March 31, 2022, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law. 

SOURCE Emmaus Life Sciences, Inc.